• Skip to global navigation
  • Skip to secondary navigation
  • Skip to main content

Thomson Reuters Logo

    • English
      • English
      • en-USEnglish
      • ja-JP日本語
      • zh-CN
  • | Contact Us
  • Home
  • Products & Services
    • Financial
    • Governance, Risk and Compliance
    • Intellectual Property
    • Legal
    • Media
    • Science
    • Tax & Accounting
  • News & Ideas
    • Press Releases
    • Media Contacts
    • Articles
    • Sustainability
    • Case Studies
    • White Papers
    • In The News
    • The Knowledge Effect
    • Euro Zone
  • Investor Relations
    • News & Events
    • Financial Information
    • Stock Information
    • Presentations
    • Dividends
    • Corporate Governance
    • Shareholder Services
  • About Us
    • Executive Team
    • Board of Directors
    • Company History
    • Sponsorships
    • The Trust Principles
    • Awards & Recognition
    • Corporate Responsibility
    • Office Locations
    • Our Websites
    • Thomson Reuters 2012 Annual Report
    • Contact Us
  • Careers
  • Science Home
  • Free Scientific Resources
  • Drug Reports
Science
  • Products & Services
  • Scholarly Research, Publishing and Analysis
  • Life Sciences Solutions
  • Support
  • Systems Biology
  • Contact Science
  • Office Locations
  • Free Scientific Resources
    • Essays
    • Life Sciences Resources
    • Drug Reports
      • Adalimumab
      • Bevacizumab
      • Celecoxib
      • Cetuximab
      • Duloxetine
      • Erlotinib
      • Etanercept
      • Imatinib
      • Infliximab
      • Pregabalin
  • Training
  • Conferences & Events

Drug Reports

Read full drug reports from Thomson Reuters. Over 40,000 are available in Thomson Reuters Cortellis for Competitive Intelligence. Find out more about Thomson Reuters Cortellis for Competitive Intelligence and take a free two week trial to see what Thomson Reuters Cortellis for Competitive Intelligence can do for you.

  • Adalimumab (trade name Humira)
  • Bevacizumab (trade name Avastin)
  • Celecoxib (trade name Celecox and Celebrex)
  • Cetuximab (trade name Erbitux)
  • Duloxetine (trade name Symbalta, Cymbalta, Xeristar, Yentreve, Ariclaim and Duloxetine Boehringer Ingelheim)
  • Erlotinib (trade name Tarceva)
  • Etanercept (trade name Enbrel and Enbrel SureClick)
  • Imatinib (trade name Gleevec and Glivec)
  • Infliximab (trade name Avakine and Remicade)
  • Pregabalin (trade name Lyrica)
© 2013 Thomson Reuters
  • Product Logins
  • Privacy Statement
  • Terms Of Use
  • Site Map
  • Copyright
  • Feedback